0000000000380529

AUTHOR

Thomas Weisenburger

showing 2 related works from this author

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

2019

All authors: Andrea Cossarizza Hyun‐Dong Chang Andreas Radbruch Andreas Acs Dieter Adam Sabine Adam‐Klages William W. Agace Nima Aghaeepour Mübeccel Akdis Matthieu Allez Larissa Nogueira Almeida Giorgia Alvisi Graham Anderson Immanuel Andrä Francesco Annunziato Achille Anselmo Petra Bacher Cosima T. Baldari Sudipto Bari Vincenzo Barnaba Joana Barros‐Martins Luca Battistini Wolfgang Bauer Sabine Baumgart Nicole Baumgarth Dirk Baumjohann Bianka Baying Mary Bebawy Burkhard Becher Wolfgang Beisker Vladimir Benes Rudi Beyaert Alfonso Blanco Dominic A. Boardman Christian Bogdan Jessica G. Borger Giovanna Borsellino Philip E. Boulais Jolene A. Bradford Dirk Brenner Ryan R. Brinkman Anna E. S. Broo…

0301 basic medicineConsensusImmunologyConsensuCell SeparationBiologyArticleFlow cytometry03 medical and health sciences0302 clinical medicineGuidelines ; Immunology ; Flow cytometryAllergy and ImmunologymedicineCell separationImmunology and AllergyHumansguidelines; flow cytometry; immunologymedicine.diagnostic_testBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Cell sortingFlow CytometryCell selectionData science3. Good health030104 developmental biologyPhenotypeAllergy and Immunology; Cell Separation; Consensus; Flow Cytometry; Humans; Phenotype[SDV.IMM]Life Sciences [q-bio]/ImmunologyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.030215 immunologyHumanEuropean journal of immunology
researchProduct

549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma pat…

2021

BackgroundLipo-MERIT is an ongoing, first-in-human, open-label, dose-escalation Phase I trial investigating safety, tolerability and immunogenicity of BNT111 in patients with advanced melanoma. BNT111 is an RNA-LPX vaccine targeting the melanoma tumor-associated antigens (TAAs) New York esophageal squamous cell carcinoma 1 (NY-ESO-1), tyrosinase, melanoma-associated antigen 3 (MAGE-A3), and transmembrane phosphatase with tensin homology (TPTE). A previous exploratory interim analysis showed that BNT111, alone or combined with immune checkpoint inhibition (CPI), has a favorable adverse event (AE) profile, gives rise to antigen-specific T-cell responses and induces durable objective responses…

PharmacologyOncologyCancer Researchmedicine.medical_specialtybusiness.industryImmunogenicityELISPOTMelanomaImmunologyInterim analysismedicine.diseaseVaccinationOncologyTolerabilityInternal medicineCutaneous melanomamedicineMolecular MedicineImmunology and AllergyAdverse effectbusinessJournal for ImmunoTherapy of Cancer
researchProduct